ReviewFrontiers in cellular and infection microbiology2019
Targeting the Gut Microbiota to Treat Cachexia.
Review in Frontiers in cellular and infection microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Cancer- and cardiac-induced cachexia: same fate through different inflammatory mediators?Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Pooled it
- Trial
- Glycine increases fat-free mass in malnourished haemodialysis patients: a randomized double-blind crossover trial.Journal of cachexia, sarcopenia and muscle · 2021Trial
- Gut microbiota in cancer cachexia: a new frontier for research and therapy.Genes & nutrition · 2025Review
- Modulating the Gut-Muscle Axis: Increasing SCFA-Producing Gut Microbiota Commensals and Decreasing Endotoxin Production to Mitigate Cancer Cachexia.Microorganisms · 2025Review
- Combating chronic kidney disease-associated cachexia: A literature review of recent therapeutic approaches.BMC nephrology · 2025Review
- Role of the intestinal microbiota in contributing to weight disorders and associated comorbidities.Clinical microbiology reviews · 2024Review
- Progress of linking gut microbiota and musculoskeletal health: casualty, mechanisms, and translational values.Gut microbes · 2023Review
- Probiotics in Orthopedics: From Preclinical Studies to Current Applications and Future Perspective.Microorganisms · 2023Review
- Polysaccharide of Ganoderma lucidum Ameliorates Cachectic Myopathy Induced by the Combination Cisplatin plus Docetaxel in Mice.Microbiology spectrum · 2023Article
- An Integrated Approach to Skeletal Muscle Health in Aging.Nutrients · 2023Review
- Targeting Gut Microbiota in Cancer Cachexia: Towards New Treatment Options.International journal of molecular sciences · 2023Review
- Amino Acids in Cancer and Cachexia: An Integrated View.Cancers · 2022Review
- Gut microbiome and pancreatic cancer cachexia: An evolving relationship.World journal of gastrointestinal oncology · 2022Article
- Gut microbes and muscle function: can probiotics make our muscles stronger?Journal of cachexia, sarcopenia and muscle · 2022Review
- Distinct composition and metabolic functions of human gut microbiota are associated with cachexia in lung cancer patients.The ISME journal · 2021Article
- Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review.Journal of molecular and cellular cardiology · 2021Review
- Review
- A Pound of Flesh: What Cachexia Is and What It Is Not.Diagnostics (Basel, Switzerland) · 2021Review
- Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia.Oncogenesis · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cachexia occurs in many chronic diseases and is associated with increased morbidity and mortality. It is treated by nutritional support but often with limited effectiveness, leading to the search of other therapeutic strategies. The modulation of gut microbiota, whether through pro-, pre-, syn- or antibiotics or fecal transplantation, is attracting ever-growing interest in the field of obesity, but could also be an interesting and innovative alternative for treating cachexia. This article reviews the evidence linking the features of malnutrition, as defined by the Global Leadership Initiative on Malnutrition [low body mass index (BMI), unintentional body weight loss, low muscle mass, low appetite, and systemic inflammation] and the gut microbiota in human adults with cachexia-associated diseases, and shows the limitations of the present research in that field with suggestions for future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.